CRO

Is Icon a buyout target?; Covance pads its executive suite;

> With its double-digit annual growth and tax-friendly Irish domicile, Icon ($ICLR) could be an M&A target. Item

> Covance ($CVD) added two vice presidents, appointing Roche ($RHHBY) veteran Robert Wasserman as head of oncology and former AstraZeneca ($AZN) exec Rogelio Mosqueda-Garcia to lead the early clinical services segment of its medical and scientific affairs business. More